4.6 Review

HES1 in immunity and cancer

Journal

CYTOKINE & GROWTH FACTOR REVIEWS
Volume 30, Issue -, Pages 113-117

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2016.03.010

Keywords

HES1; NOTCH; Cancer; Immunity; Cytokine; Therapy

Funding

  1. Medical Research Council [MR/J006742/1] Funding Source: Medline
  2. Medical Research Council [MR/J006742/1] Funding Source: researchfish

Ask authors/readers for more resources

Hairy and enhancer of split homolog-1 (HES1) is a part of an extensive family of basic helix -loop -helix (bHLH) proteins and plays a crucial role in the control and regulation of cell cycle, proliferation, cell differentiation, survival and apoptosis in neuronal, endocrine, T-lymphocyte progenitors as well as various cancers. HES1 is a transcription factor which is regulated by the NOTCH, Hedgehog and Wnt signalling pathways. Aberrant expression of these pathways is a common feature of cancerous cells. There appears to be a fine and complicated crosstalk at the molecular level between the various signalling pathways and HES1, which contributes to its effects on the immune response and cancers such as leukaemia. Several mechanisms have been proposed, including an enhanced invasiveness and metastasis by inducing epithelial mesenchymal transition (EMT), in addition to its strict requirement for tumour cell survival. In this review, we summarize the current biology and molecular mechanisms as well as its use as a clinical target in cancer therapeutics. (C) 2016 Published by Elsevier Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available